An ultra-rare kidney disease that can become life-threatening now has its first FDA ... the drug expanded its approval to include the rare autoimmune kidney disease IgA nephropathy. Novartis ...

The approval Vanrafia marks the third drug approval for Novartis in its renal disease portfolio. Shares of Novartis have risen 16.5% year to date compared with the large cap pharmaceutical ...

In early April, Novartis drug Vanrafia won accelerated FDA approval as ... becoming the first FDA-approved treatment for C3 glomerulopathy, an ultra-rare kidney disease that can progress to ...

Novartis has claimed accelerated approval from the FDA for Vanrafia ... the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia (atrasentan) is the first drug in the selective ...

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

If Regulus’ lead drug candidate, farabursen, gets regulatory approval ... Novartis – which has its U.S. headquarters in East Hanover – said the move will strengthen its lineup of kidney ...

The IgA nephropathy treatment approach aims to reduce proteinuria, manage blood pressure, and slow the progression of the disease ... encouraging results. FDA-approved drugs for IgA nephropathy ...

Novartis to acquire Regulus for $7/share upfront, a 108% premium to April 29 close and 274% over 60-day VWAP. The total deal could reach $1.7 billion if farabursen gains regulatory approval, with ...

(Reuters) -Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental drug to treat a life-threatening kidney disease. Under the ...